Advertisement

Medical Oncology

, 30:450 | Cite as

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study

  • Kazunari Tateishi
  • Takashi Ichiyama
  • Kazuya Hirai
  • Toshihiko Agatsuma
  • Shigeru Koyama
  • Tsutomu Hachiya
  • Nobutoshi Morozumi
  • Takayuki Shiina
  • Tomonobu KoizumiEmail author
Original Paper

Abstract

The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations were analyzed retrospectively. We analyzed chemotherapy-naïve NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once daily in Nagano Prefecture. A total of 55 patients (16 men, 39 women) with a median age of 81.1 years (range; 75–94 years) treated between April 2007 and July 2012 were analyzed. The overall response rate and disease control rate were 72.7 % (95 % confidence interval (CI); 59.5–82.9 %) and 92.7 % (95 % CI; 82.0–97.6 %), respectively. Median progression-free survival and overall survival from the start of gefitinib treatment were 13.8 months (95 % CI; 9.9–18.8 months) and 29.1 months (95 % CI; 22.4 months–not reached), respectively. Two-year survival rate was 59.5 % (95 % CI; 41.0–78.0 %). Major grade 3 toxicities were skin rash (1.8 %) and increased levels of aspartate aminotransferase or alanine aminotransferase (7.3 %). First-line treatment with gefitinib for elderly EGFR-mutated NSCLC patients was effective and well tolerated. The results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations.

Keywords

Non-small-cell lung cancer Elderly patients First-line EGFR mutations Gefitinib 

Notes

Acknowledgments

We thank the patients and their families for their support and participation in this study. We also thank Akihiro Tsukadaira in Iida Municipal Hospital, Muneharu Hayasaka in Chushin Matsumoto Hospital, Akio Morokawa in Showa Inan Hospital, and all of the members of Nagano Lung Cancer Research Group for their helpful support.

Conflict of interest

None.

References

  1. 1.
    Matsuda T, Marugame T, Kamo K, et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42:139–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Marugame T, Matsuda T. Comparison of time trends in lung cancer incidence (1973–2002) in Asia, from cancer incidence in five continents Vols IV-IX. Jpn J Clin Oncol. 2009;39:133–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med. 1993;14:453–78.PubMedGoogle Scholar
  4. 4.
    Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Azzoli CG, Baker S Jr, Temin S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol. 2009;27:6251–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:173–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Provencio M, Camps C, Alberola V, et al. Lung cancer and treatment in elderly patients: the Achilles study. Lung Cancer. 2009;66:103–6.PubMedCrossRefGoogle Scholar
  9. 9.
    The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 1999;91:66–72.CrossRefGoogle Scholar
  10. 10.
    Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan thoracic oncology group trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Inoue A, Kobayashi K, Usui K, et al. North East Japan gefitinib study group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394–400.PubMedCrossRefGoogle Scholar
  13. 13.
    Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Asami K, Koizumi T, Hirai K, Ameshima S, et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer. 2011;12:387–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7:1417–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Travis WD, Colby TV, Corrin B et al. Histological typing of lung and pleural tumors. World Health Organization international histological classification of tumors. 3rd ed. Berlin: Springer; 1999.Google Scholar
  20. 20.
    Travis WD, Brambilla E, Muller-Hermelink HK et al. Pathology and genetics. Tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.Google Scholar
  21. 21.
    Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposalsfor the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Title of subordinate document. In: Common terminology criteria for adverse events (CTCAE) Version 4.0. National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 of subordinate document (2012). Accessed 28 Nov 2012.
  24. 24.
    Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. 2012;17:863–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Kazunari Tateishi
    • 1
  • Takashi Ichiyama
    • 1
  • Kazuya Hirai
    • 2
  • Toshihiko Agatsuma
    • 3
  • Shigeru Koyama
    • 4
  • Tsutomu Hachiya
    • 5
  • Nobutoshi Morozumi
    • 6
  • Takayuki Shiina
    • 7
  • Tomonobu Koizumi
    • 8
    Email author
  1. 1.First Department of Internal MedicineShinshu UniversityMatsumoto CityJapan
  2. 2.Department of Pulmonary DiseasesNagano Municipal HospitalNagano CityJapan
  3. 3.Department of Respiratory MedicineNational Hospital Organization Shinshu Ueda Medical CenterUeda CityJapan
  4. 4.Department of Pulmonary DiseasesNagano Red Cross HospitalNagano CityJapan
  5. 5.Department of Pulmonary DiseasesSuwa Red Cross HospitalSuwa CityJapan
  6. 6.Department of Pulmonary DiseaseSaku Central HospitalSaku CityJapan
  7. 7.Department of Second SurgeryShinshu UniversityMatsumoto CityJapan
  8. 8.Division of Clinical Oncology, Comprehensive Cancer CenterShinshu University HospitalMatsumotoJapan

Personalised recommendations